Key Points
- Glaukos CEO Thomas William Burns sold 88,055 shares on Jan. 8 at $115 (~$10.13M) and 186,945 shares on Jan. 16 at $115 (~$21.50M), reducing his stake to 153,775 shares—a 36.41% ownership drop.
- The stock was trading up ~2.5% (opened $123.19) amid analyst price-target increases and a consensus "Moderate Buy" with a $127.92 target, while the company reported revenue up 38.1% year-over-year and an EPS loss smaller than expected.
Glaukos Corporation (NYSE:GKOS - Get Free Report) CEO Thomas William Burns sold 88,055 shares of the company's stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $115.00, for a total transaction of $10,126,325.00. Following the sale, the chief executive officer owned 153,775 shares in the company, valued at $17,684,125. The trade was a 36.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Thomas William Burns also recently made the following trade(s):
- On Friday, January 16th, Thomas William Burns sold 186,945 shares of Glaukos stock. The stock was sold at an average price of $115.00, for a total transaction of $21,498,675.00.
Glaukos Trading Up 2.5%
NYSE GKOS opened at $123.19 on Wednesday. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $163.71. The firm has a 50 day moving average of $108.62 and a two-hundred day moving average of $95.74. The company has a quick ratio of 4.47, a current ratio of 5.20 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $7.08 billion, a PE ratio of -79.99 and a beta of 0.67.
Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.11. The business had revenue of $133.54 million for the quarter, compared to analyst estimates of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The company's revenue was up 38.1% on a year-over-year basis. During the same period last year, the business earned ($0.28) EPS. As a group, research analysts expect that Glaukos Corporation will post -1.08 EPS for the current fiscal year.
Institutional Investors Weigh In On Glaukos
Several large investors have recently modified their holdings of GKOS. Wellington Management Group LLP grew its position in shares of Glaukos by 10.4% during the third quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier's stock worth $292,004,000 after acquiring an additional 336,266 shares during the last quarter. Primecap Management Co. CA raised its position in Glaukos by 23.3% in the 3rd quarter. Primecap Management Co. CA now owns 2,253,788 shares of the medical instruments supplier's stock valued at $183,796,000 after purchasing an additional 425,790 shares during the last quarter. State Street Corp raised its position in Glaukos by 5.3% in the 2nd quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier's stock valued at $215,914,000 after purchasing an additional 105,972 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in Glaukos by 3.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier's stock worth $206,503,000 after purchasing an additional 68,497 shares during the period. Finally, Alliancebernstein L.P. boosted its stake in Glaukos by 38.5% during the 3rd quarter. Alliancebernstein L.P. now owns 1,733,474 shares of the medical instruments supplier's stock worth $141,365,000 after purchasing an additional 481,620 shares during the period. 99.04% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
GKOS has been the topic of a number of recent analyst reports. Wells Fargo & Company increased their price objective on Glaukos from $120.00 to $122.00 and gave the company an "overweight" rating in a report on Thursday, October 30th. Truist Financial upped their price target on Glaukos from $120.00 to $145.00 and gave the company a "buy" rating in a report on Thursday, December 18th. Stephens increased their price target on shares of Glaukos from $115.00 to $145.00 and gave the company an "overweight" rating in a research note on Friday, January 2nd. Needham & Company LLC reissued a "buy" rating and set a $125.00 price objective on shares of Glaukos in a report on Wednesday, January 14th. Finally, The Goldman Sachs Group restated a "buy" rating and issued a $138.00 target price on shares of Glaukos in a report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $127.92.
View Our Latest Report on Glaukos
About Glaukos
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
